World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma

Martel, Catherine de; Maucort-Boulch, Delphine; Plummer, Martyn; Franceschi, Silvia

doi:10.1002/hep.27969

Cited by 421 publications

(358 citation statements)

References 33 publications

Supporting

Mentioning

346

Contrasting

Unclassified

Order By: Relevance

“…Patients who received sorafenib and HAIC, and for whom frozen serum was available, were not artificially enrolled in this study. However, the frequency of patients with HBV was higher than the usual case for HCC patients in Japan [42,43].…”

Section: Patients Treated With Haic Treatmentmentioning

confidence: 69%

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

et al. 2017

View full text Add to dashboard Cite

Background Biomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated with poor prognosis for patients with HCC. The purpose of this study was to assess serum HMGB1 concentrations before and during sorafenib treatment or hepatic arterial infusion chemotherapy (HAIC) and to explore the ability of serum HMGB1 concentrations to predict prognosis. Methods Serum HMGB1 concentrations were measured in 71 and 72 patients with advanced HCC treated with sorafenib and HAIC, respectively, to assess their usefulness for prediction of the response to the treatment and prognosis. Results Multivariate analysis identified high HMGB1 at 4 weeks (P = 0.001), high a-fetoprotein (AFP) at baseline (P = 0.025), tumor liver occupying rate (P = 0.009) and modified RECIST (mRECIST, P \ 0.0001) as independent Kazuhiko Masuda and Atsushi Ono are the co-first authors.The original version of this article was revised: An article note about co-first authorship was added and the second sentence in the subheading ''Results'' under the ''Abstract'' section was corrected. predictors of poor overall survival in sorafenib treatment. High HMGB1 at 4 weeks (P = 0.025), vascular invasion to the hepatic vein (Vv) (P = 0.009), mRECIST (P \ 0.0001) and Child-Pugh B (P = 0.004) were identified as independent predictors of poor overall survival in HAIC treatment. The concentrations of HMGB1 at baseline and 4 weeks were not correlated with conventional tumor markers and progressive disease assessed by mRECIST at 8 weeks.Conclusions These results suggest that serum HMGB1 at 4 weeks after the start of treatment might be a useful biomarker with added value to the conventional tumor marker and radiologic responses to predict poor overall survival in patients with advanced HCC treated with sorafenib or HAIC.

show abstract

Section: Patients Treated With Haic Treatmentmentioning

confidence: 69%

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Liver cancer cases mostly occur in Africa and Asia, where the high number of hepatitis B and hepatitis C cases strongly predisposes to the development of liver disease and the subsequent development of liver cancer (6,7). Consequently, comprehensive elucidation of the mechanisms governing recurrence of liver cancer and metastasis are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

miRNA-346 promotes proliferation, migration and invasion in liver cancer

Xia

Duan

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Liver cancer primarily accounts for the majority of malignancies of the liver. MicroRNAs (miRNAs) are endogenous non-coding RNAs, which are important in tumorigenesis. Abnormal expression of microRNA-346 (miR-346) has been demonstrated in various types of human cancer, however, its expression and potential molecular mechanism in liver cancer remains to be elucidated. Expression levels of miR-346 in liver cancer cell lines were determined by quantitative polymerase chain reaction. The effect of miR-346 on proliferation was evaluated by an MTT assay; cell migration and invasion were evaluated by Transwell migration and invasion assays and target protein expression was determined by western blotting. The present study observed that miR-346 was upregulated in liver cancer cell lines. miR-346 overexpression promoted cell proliferation, migration and invasion in liver cancer cells and conversely, inhibition of miR-346 resulted in the opposite effects. Furthermore, F-Box and leucine rich repeat protein (FBXL)2 was identified as a direct target of miR-346. miR-346 promoted proliferation, migration and invasion of liver cancer via FBXL2. Overall, these findings demonstrated that miR-346 may act as a potential prognostic marker and therapeutic target against liver cancer in the future.

show abstract

“…Evidence from a systematic review of HCC case series has also shown younger ages at diagnosis of HBVrelated HCC in sub-Saharan Africa than in Asia. 2 Drawing such conclusions from case series is questionable, because the median age at HCC diagnosis can be strongly affected by the underlying population's age distribution. Indeed, the median age of the population in sub-Saharan Africa is lower than in Egypt (18 vs 25 years), 3 reflecting the higher risks for competing causes of death in sub-Saharan Africa.…”

Section: Main Textmentioning

confidence: 99%